Skip to content

Exacerbation and Training in Patients With Chronic Obstructive Pulmonary Disease

Exacerbation and Training - Study; a Randomized Controlled Study of the Effect of Resistance Training in Acute Exacerbations of COPD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00877084
Acronym
EXTRA
Enrollment
40
Registered
2009-04-07
Start date
2004-01-31
Completion date
2008-12-31
Last updated
2009-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

exacerbation, COPD, Resistance training, Muscle force

Brief summary

When patients with chronic obstructive lung disease (COPD) are admitted to the hospital with a severe exacerbation they lose muscle strength. This muscle weakness predisposes these patients to further hospital admissions. Resistance training is a potent countermeasure to prevent and treat muscle weakness. In the setting of an acute exacerbation this intervention however has not been validated. The present study aims at investigating the safety and efficacy of resistance training (3x8 quadriceps extensions per day) to prevent muscle weakness. End points are quadriceps muscle strength and hospital readmission and functional status at discharge. Using the minimally invasive needle muscle biopsy technique described by Bergström the effects of resistance training on the skeletal muscle will be analyzed in detail. After giving informed consent, patients will be randomized on admission into usual care or usual care plus resistance training. Patients will be followed-up using the clinical pathway for COPD (10 days). After one month patients will attend the outpatient clinic for a follow-up visit. Besides the measurement prescribed in the clinical path for COPD (including arterial blood gas measures, lung function, functional investigation of the patients), patients will undergo muscle strength measures and venous blood will be drawn for the analysis of systemic inflammatory and growth factors. Half of the patients will receive a resistance training program. At the end of the hospital admission, a needle biopsy of the vastus lateralis muscle will be obtained.

Interventions

OTHERResistance training

Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.

OTHERUsual care

usual care according to clinical pathway for COPD, No training

Sponsors

KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No

Inclusion criteria

* COPD exacerbation, admitted to the respiratory units * Informed consent * Age \< 80 * No critical comorbidity compromising outcome up to one month. * No suspect of malignancy

Exclusion criteria

* Patient is involved in a rehabilitation program with a frequency \>1/wk during one month after inclusion in the study * NIMV or ICU on admission * Patient scheduled for procedure (LTX/LVRS) within one month after discharge * Readmission \<14 days after previous hospitalization * Significant pathology that would hinder the participation in resistance training (gonarthrosis, arthritis to be judged by the investigator) * Clinical signs of pulmonary hypertension

Design outcomes

Primary

MeasureTime frame
Reduction in the decline of muscle force during the exacerbation.discharge Day 9

Secondary

MeasureTime frame
Time to readmission or death6 Months
Functional exercise capacity at discharge (6MWT)discharge Day 9
Functional exercise capacity and muscle force at 1 month1 Month
Markers of systemic inflammation and oxidative stress in serum and muscle of patients at day 9 of the exacerbation.Day 9

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026